To kick off our 2023 Year in Review, Josh looks back at some of our top articles and coverage from the year.
With several subcommittee cancellations and an abbreviated meeting of the full board in November, the Natural Medicine Advisory Board (NMAB) had quite a bit of ground to cover in December to meet their goal of submitting an annual progress report in early 2024. Here, we review December’s meetings.
Dozens of new psychedelics studies are unable to commence in California, despite having clearance from the likes of the FDA and DEA. The backlog is costing millions of dollars and hamstringing one of the country’s most fruitful geographies for psychedelic research. Here—in the first reporting on the matter—we look at the obscure advisory panel causing the blockage and what might be done to resolve it.
This month: Patent Filings Provide First Look at atai’s NCEs • Stamets Stacks Up Two New Allowances • and more…
Here, we take a closer look at MAPS PBC’s Series A, rebrand, and what this might tell us about an organisation that so desperately wants to do things differently in an industry that’s often a case study for inertia.